NEFL Antibody (OASA00358)
- Known as:
- NEFL Antibody (OASA00358)
- Catalog number:
- oasa00358
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- NEFL Antibody (OASA00358)
Related genes to: NEFL Antibody (OASA00358)
- Gene:
- NEFL NIH gene
- Name:
- neurofilament light
- Previous symbol:
- -
- Synonyms:
- NFL, CMT1F, CMT2E, NF68, PPP1R110
- Chromosome:
- 8p21.2
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: NEFL Antibody (OASA00358)
Related articles to: NEFL Antibody (OASA00358)
- Headache is one of the most frequent reasons for emergency department (ED) visits, and distinguishing primary from secondary headache remains challenging. Blood biomarkers may improve early risk stratification. This study evaluates serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) as potential biomarkers in patients presenting with non-traumatic headache to the ED. - Source: PubMed
Camerin Sara-JessicaAtila CihanBlum Claudine ASandgren SofiaMaleska AleksandraPapadopoulou AthinaKuhle JensKatan MiraChrist-Crain Mirjam - Circulating brain injury biomarker levels increase after transsphenoidal surgery for pituitary tumors. However, their relationship with long-term fatigue and cognitive outcomes remains unclear. We investigated whether postoperative changes in glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and tau are associated with fatigue and cognitive outcomes in patients with nonfunctioning pituitary adenomas (NFPAs). - Source: PubMed
Publication date: 2026/07/01
Eyglóardóttir KristinSkoglund ThomasHantelius VictorRagnarsson OskarKrabbe DavidSunnerhagen Katharina SJakobsson SofieZetterberg HenrikJohannsson GudmundurHallén Tobias - Apolipoprotein E () ε4 is a well-known risk factor for Alzheimer's disease (AD), with ε4 carriers exhibiting distinct clinical and biological characteristics compared to non-carriers. This study investigated whether the predictive performance of plasma biomarkers for amyloid positron emission tomography (PET) outcomes varies by ε4 carrier status in individuals with subjective cognitive decline (SCD). - Source: PubMed
Publication date: 2026/06/29
Lee Hyuk-JeYoon BoraHong Yun JeongJeong Jee HyangKim SangYunWang Min JeongChoi Seong HyeRyu Ji SunKang SungminPark Kee HyungYang Dong Won - Advances in ultrasensitive immunoassays have enabled reliable quantification of neuroglial biomarkers in blood, providing valuable insights into neurological disorders. However, cross-platform evaluations are necessary to ensure comparability and standardization. This study aimed to compare the analytical performance of a Single Molecule Array (Simoa) and an ultrasensitive electrochemiluminescence (ECL) assay for quantifying neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in human serum. Baseline serum samples from 174 participants in the RIFUND trial were analyzed in parallel on both platforms. Concentrations of NfL and GFAP were compared using Spearman correlation, Bland-Altman analyses, reproducibility assessments, dilution linearity, and cross-platform recovery. All samples were quantifiable on both platforms. NfL concentrations correlated strongly between methods (Spearman correlation r = 0.88, p < 0.0001), whereas GFAP correlated moderately (r = 0.77, p < 0.0001). Inter- and intra-assay coefficients of variation were comparable between platforms for both analytes. The relationship between the two assays could be described with the following equations: NfL = 7.63 × NfL + 1.71 and GFAP = 0.332 × GFAP + 4.22. Dilution linearity was excellent on both platforms (R > 0.99), although cross-platform recovery varied systematically across the analytical range. Both Simoa and ECL demonstrated strong analytical performance for neuroglial biomarker quantification in serum. Despite systematic differences in absolute concentrations, relative agreement was high, particularly for NfL. These findings highlight the need for platform harmonization and provide empirically derived conversion factors to support analytical comparability in research and clinical applications. - Source: PubMed
Publication date: 2026/06/30
Aulin JuliaAl-Grety AsmaSjölin KarlErngren IdaLarsson AndersSvenningsson AndersKultima KimBurman Joachim - Immune signaling alterations have been implicated in Alzheimer's disease (AD) pathophysiology, but their heterogeneity across the disease continuum in real-world cohorts is poorly characterized, limiting the development of stratified immunomodulatory approaches. - Source: PubMed
Birditt Katherine RMavromati KalliopiSwann PeterQuinn TerenceHainsworth Atticus HHughes LynneO'Brien John TMcEwan WilliamMalpetti Maura